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Background	
	
¥  Neoadjuvant	therapy	for	resectable	pancrea5c	cancer	is	controversial	
¥  Current	guidelines	support	resec5on	followed	by	adjuvant	therapy.		
¥  However,	up	to	50%	of	pa5ents	fail	to	receive	adjuvant	therapy	due	to:	
¥  	post-opera5ve	complica5ons	
¥  early	disease	reoccurrence	
¥  decline	in	func5on.	
¥  Beneﬁts	of	neoadjuvant	therapy	include:		
¥  elimina5on	of	micrometastases	
¥  Increased	mul5modal	treatment	obtainment	
¥  Increased	R0	resec5on	rates	
¥  Filtering	pa5ents	with	more	aggressive	tumours	away	
from	expensive,	high	risk	surgery	that	would	ul5mately	
be	fu5le.	
¥  Risks	of	neoadjuvant	therapy:	losing	window	of	resectability	
¥  No	large	mul5centre	randomized	controlled	trials	oﬀering	head-to-head	
comparison	of	treatment	strategies		
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Aims	
¥  To	analyse	the	cost-eﬀec5veness	of	neoadjuvant	therapy	(NAT)	versus	surgery-ﬁrst	(SF)	
treatment	pathways	for	resectable	pancrea5c	cancer.		
¥  Primary	and	secondary	outcome	measures:	Beneﬁts	were	measured	as	QALMs	with	cost-
eﬀec5veness	presented	as	incremental	costs,	incremental	eﬀec5veness,	cost-eﬀec5veness	
ra5o,	incremental	cost-eﬀec5veness	ra5o	and	incremental	net	monetary	beneﬁt.		
	
¥  The	study	was	conducted	from	a	Na5onal	Health	Service	
(UK)	perspec5ve		
¥  Discoun5ng	of	costs	and	beneﬁts	set	at	3.5%	
¥  	Willingness-to-pay	set	at	£2,500	per	quality-adjusted-life-
month	(QALM)	(£30,000	per	quality-adjusted-life-year)		
¥  A	Markov	model	with	1-month	cycle	length	set	to	a	
maximum	follow-up	5me	of	60-cycles	was	created	to	
es5mate	incremental	life5me	costs	and	beneﬁts.	
Determinis5c	and	probabilis5c	sensi5vity	analysis	was	
undertaken	to	test	model	uncertain5es	including	
alterna5ve	discoun5ng	rates.		
In	the	absence	of	large	randomized	controlled	trial,	model	
transi5on	probabili5es	were	calculated	from	meta-analysis	
of	weighted	pooled	propor5ons	following	comprehensive	
search	of	MEDLINE,	Embase,	PubMed	and	Cochrane	
database	and	Cochrane	database	of	Clinical	Trials,	RCTs,	
phase	II	and	III	trials.		
NAT	gave	21.27	QALMs	at	a	cost	of	£92957.30	with	a	cost-
eﬀec5veness	ra5o	of	£4370.73.	SF	gave	17.59	QALMs	at	a	
cost	of	£98188.63	and	a	cost-eﬀec5veness	ra5o	of	
£5582.85.	SF	therefore	had	an	incremental	cost	of	
£5231.33	more	than	NAT	for	an	incremental	eﬀec5veness	
of	-3.68	QALMs	and	an	incremental	cost-eﬀec5veness	
ra5o	of	-£1421.33	making	NAT	the	most	cost-eﬀec5ve	
op5on.		
	
Conclusion	
	
Based	on	best	available	current	evidence	we	found	
that	NAT	is	cost-eﬀec5ve	for	the	management	of	
resectable	pancrea5c	cancer.		
	
However,	as	high-quality	data	from	emerging	RCTs	
becomes	available	further	cost-eﬀec5veness	analysis	is	
required.				
	
There	remains	the	possibility	that	pa5ents	with	earliest	
resectable	disease	most	likely	to	receive	R0	resec5on	
and	adjuvant	therapy	may	s5ll	beneﬁt	from	upfront	
surgery	approach		
	
Message	For	Others	
	
Cost-eﬀec5veness	analysis	adds	an	important	
dimension	to	the	debate	about	compe5ng	
treatment	op5ons	for	resectable	pancrea5c	
cancer.	Costs	and	beneﬁts	In	cancer	treatment	are	
mul5faceted	and	complex	requiring	greater	
pa5ent	and	carer	input	in	future	research	which	
should	coincide	with	a	move	towards	
personalised	predic5ve	medicine	in	research	to	
support	shared	clinical	decision-making.		
	
Future	Direc7on	
	
Quality-of-life	data	for	pancrea5c	
cancer	is	limited	and	this	should	be	the	
focus	of	further	research	as	costs	and	
beneﬁts	in	cancer	care	are	complex	
with	quality	as	well	as	quan5ty	of	
survival	5me	having	great	importance.	
Although	neoadjuvant	pathway	was	
more	cost-eﬀec5ve,	this	depended	on	
receiving	mul5modal	treatment.	This	
highlights	the	need	moving	towards	
personalised	predic5ve	medicine	to	
support	shared	decision-making	in	
research	and	prac5ce.						
